ONC (BeOne Medicines) Long-Term Debt: $963 Mil (As of Mar. 2026)


ONC BeOne Medicines Ltd ONC
79 GF Score
Price $300.10
GF Value $357.86
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BeOne Medicines Long-Term Debt?

BeOne Medicines ONC -2.87% 79 Long-Term Debt is $963 Mil as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $357.86 (Modestly Undervalued). The stock has 3 warning signs investors should review.

BeOne Medicines's Long-Term Debt for the quarter that ended in Mar. 2026 was $963 Mil.

BeOne Medicines's quarterly Long-Term Debt increased from Sep. 2025 ($140 Mil) to Dec. 2025 ($962 Mil) and increased from Dec. 2025 ($962 Mil) to Mar. 2026 ($963 Mil).

BeOne Medicines's annual Long-Term Debt declined from Dec. 2023 ($198 Mil) to Dec. 2024 ($166 Mil) but then increased from Dec. 2024 ($166 Mil) to Dec. 2025 ($962 Mil).

BeOne Medicines  (NAS:ONC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BeOne Medicines Long-Term Debt Related Terms

BeOne Medicines Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Long-Term Debt Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 202.11 209.15 197.62 166.48 961.91

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.16 146.09 139.57 961.91 962.52
ONC
79GF Score
BeOne Medicines Ltd ONC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $963 Mil mean?
BeOne Medicines (ONC) has a Long-Term Debt of $963 Mil as of Mar. 2026.
Is BeOne Medicines' Long-Term Debt too high?
BeOne Medicines' current Long-Term Debt is $963 Mil. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Long-Term Debt compare to MRNA and RPRX?
BeOne Medicines' Long-Term Debt of $963 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BeOne Medicines's current Long-Term Debt is $963 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $357.86, compared to a current price of $300.10 — trading 16.1% below its estimated fair value. The current Long-Term Debt is $963 Mil. BeOne Medicines' overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Long-Term Debt is $963 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $300.10 is trading 16.1% below its estimated GF Value™ of $357.86. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Long-Term Debt: $963 Mil
  • GF Value™: $357.86 vs. price of $300.10 (16.1% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$300.10
Price
$357.86
GF Value